2013-06030. Institutional Review Boards; Correcting Amendments  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule; correcting amendments.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending its regulations regarding institutional review boards to address a minor correction to the regulatory text and to update contact information. This action is editorial in nature and is intended to provide accuracy and clarity to the Agency's regulations.

    DATES:

    This final rule is effective March 15, 2013.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Kathleen Pfaender, Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5172, Silver Spring, MD 20993, 301-796-8346.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    FDA is amending 21 CFR part 56 to correct a minor error in the Code of Federal Regulations (CFR), and to update obsolete information. A minor spelling error was introduced inadvertently in the CFR when the regulations were first published. Also, contact information in the regulations is obsolete and in need of updating.

    Publication of this document constitutes final action under the Administrative Procedures Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to correct minor errors and to update obsolete information, and is nonsubstantive.

    Start List of Subjects

    List of Subjects in 21 CFR Part 56

    • Human research subjects
    • Reporting and reporting requirements, and Safety
    End List of Subjects

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 56 is amended as follows:

    Start Part

    PART 56—INSTITUTIONAL REVIEW BOARDS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 56 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 343, 346, 346a, 348, 350a, 350b, 351, 352, 353, 355, 360, 360c-360f, 360h-360j, 371, 379e, 381; 42 U.S.C. 216, 241, 262, 263b-263n.

    End Authority Start Amendment Part

    2. In § 56.106 revise paragraph (d) to read as follows:

    End Amendment Part
    Registration.
    * * * * *

    (d) Where can an IRB register? Each IRB may register electronically through http://ohrp.cit.nih.gov/​efile. If an IRB lacks the ability to register electronically, it must send its registration information, in writing, to the Office of Good Clinical Practice, Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993.

    * * * * *
    Start Amendment Part

    3. Section 56.107 is amended in paragraph (a), by revising the 3rd sentence to read as follows:

    End Amendment Part
    IRB membership.

    (a) * * * In addition to possessing the professional competence necessary to review the specific research activities, the IRB shall be able to ascertain the acceptability of proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice. * * *

    * * * * *
    Start Signature

    Dated: March 12, 2013.

    Leslie Kux,

    Assistant Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2013-06030 Filed 3-14-13; 8:45 am]

    BILLING CODE 4160-01-P

Document Information

Comments Received:
0 Comments
Effective Date:
3/15/2013
Published:
03/15/2013
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule; correcting amendments.
Document Number:
2013-06030
Dates:
This final rule is effective March 15, 2013.
Pages:
16401-16401 (1 pages)
Docket Numbers:
Docket No. FDA-2013-N-0003
Topics:
Human research subjects, Reporting and recordkeeping requirements, Safety
PDF File:
2013-06030.pdf
CFR: (2)
21 CFR 56.106
21 CFR 56.107